Current and future therapeutic trends of Ondansetron practice
Changing trend of Anti-emetic drugs practice in the management of patient with
of nausea-vomiting associated with chemotherapy, Prevention of nausea
& vomiting associated with radiotherapy, Prevention of
post-operative nausea & vomiting, Nausea-vomiting in gastroenteritis
and Nausea vomiting in pregnancy, is the market reality.
In the year 2016, an around 29% doctors used to prefer Ondansetron
whenever indication for a Anti-emetic drugs
came-across in clinical management. Presently, an approx 30% doctors prefer
Ondansetron for clinical indication;
is expected to increase further 39% over the
forecast period of 2020 - 2022.
A simultaneous declined preference is expected in other Anti-emetic drugs.
In addition, an increase incidence of
related diseases are presumed to be the
key contributing factors providing a
fillip this generic vertical.
Increased awareness, availability of
drugs by the key companies, rising
demand for improved healthcare are some of the major factors.
Furthermore, the presence of high unmet
clinical needs with regard to treatment issue is the factor propelling
the expansion of this vertical. This modality of treatment is expected
to gain popularity in the coming years as generic provides better
Get Registered for more detail